Ileana María Madrigal Beas
Research Subjects
Ileana María Madrigal Beas has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Blanca María Morfín-Maciel
Hospital san Angel Inn Chapultepec, Ciudad de México
3 shared publications - Andrea Aída Velasco-Medina
Department of Allergy, Hospital General de Mexico, Mexico City 06720, Mexico
2 shared publications - Antonio Albarrán Godínez
Servicio de Alergia e Inmunología Clínica, Hospital General de México, "Dr. Eduardo Liceaga", Mexico
2 shared publications - Eduardo Enrique Piñeyro Beltrán
Clínica de ISSTE Especialidades Dr. Pedro Barcena Hiriart, San Luis Potosí, Mexico
2 shared publications - Freya Helena Campos Romero
Hospital Central Sur de Alta especialidad, PEMEX, Mexico
2 shared publications - Guillermo Guidos Fogelbach
Instituto Politécnico Nacional, México
2 shared publications
Latest Publications
- Open Access
- 12 May 2026
- Published by MDPI AG in Preprints.org
Diagnosis and Management of Hereditary Angioedema in Latin America: International Recommendations and Regional Practice Realities
Background: Current international hereditary angioedema (HAE) guidelines and treat-to-target recommendations consistently emphasize accurate diagnosis, early on-demand treatment of attacks, appropriate short-term prophylaxis for procedures, individualized long-term prophylaxis (LTP), and routine assessment of disease control and quality of life. Published information on how these recommendations are implemented in Latin America remains limited. We therefore aimed to assess the extent to which a Latin American expert panel converges with recommendations across current international HAE guidelines and consensus documents and to identify the principal barriers affecting real-world implementation in the region. Methods: A scientific committee developed and externally validated a 74-item questionnaire (domains summarized in Supplementary Table S1) and conducted a 2-round Delphi process among Latin American HAE experts. Consensus items were rated on a 9-point agreement scale, with consensus defined a priori as at least two-thirds of panelists scoring within a 3-point band in the agreement (7-9) or disagreement (1-3) range. Descriptive items captured expert-reported diagnostic testing, acute and preventive treatment patterns, monitoring practices, and implementation determinants using 5-point Likert scales. Instrument validation (July-November 2024) demonstrated high inter-rater agreement (Kendall W = 0.84; p < 0.001) and excellent internal consistency (Cronbach alpha = 0.92). Results: Thirty experts from 10 countries completed the process (Argentina, Brazil, Chile, Colombia, Ecuador, Mexico, Panama, Peru, Uruguay, Venezuela). Panel consensus broadly converged with recommendations across current international HAE guidelines and consensus documents on core diagnostic work-up (C4 plus C1-INH antigen and function; 84% consensus), selective use of genetics (97% consensus), first-line targeted LTP (pdC1-INH, Lanadelumab, Berotralstat; 94% consensus), retention of on-demand therapy for breakthrough attacks and for patients without access to LTP, routine monitoring, and management in special populations. The principal novel finding was an implementation feasibility gap: frequent or constant interruptions in prophylaxis supply were reported by 19/30 experts (63%), including 13/23 (57%) practicing in settings where public or insurance coverage was reported. Across the panel, cost (19/30; 63%) and medicine availability (8/30; 27%) were the most commonly cited barriers, with additional constraints related to diagnostic testing access and administrative pathways. Conclusions: Latin American expert consensus largely converges with recommendations across current international HAE guidelines and consensus documents on diagnosis, acute management, prophylaxis selection, monitoring, and special-population care. The dominant divergence is not clinical disagreement but implementation feasibility—particularly access to diagnostic testing, financing mechanisms, medicine availability, and continuity of supply. These findings provide region-specific evidence to contextualize international recommendations and support implementation strategies tailored to Latin America.
- 12 May 2026
- Published by MDPI AG in Preprints.org
Open AccessDiagnosis and Management of Hereditary Angioedema in Latin America: International Recommendations and Regional Practice Realities
Background: Current international hereditary angioedema (HAE) guidelines and treat-to-target recommendations consistently emphasize accurate diagnosis, early on-demand treatment of attacks, appropriate short-term prophylaxis for procedures, individualized long-term prophylaxis (LTP), and routine assessment of disease control and quality of life. Published information on how these recommendations are implemented in Latin America remains limited. We therefore aimed to assess the extent to which a Latin American expert panel converges with recommendations across current international HAE guidelines and consensus documents and to identify the principal barriers affecting real-world implementation in the region. Methods: A scientific committee developed and externally validated a 74-item questionnaire (domains summarized in Supplementary Table S1) and conducted a 2-round Delphi process among Latin American HAE experts. Consensus items were rated on a 9-point agreement scale, with consensus defined a priori as at least two-thirds of panelists scoring within a 3-point band in the agreement (7-9) or disagreement (1-3) range. Descriptive items captured expert-reported diagnostic testing, acute and preventive treatment patterns, monitoring practices, and implementation determinants using 5-point Likert scales. Instrument validation (July-November 2024) demonstrated high inter-rater agreement (Kendall W = 0.84; p < 0.001) and excellent internal consistency (Cronbach alpha = 0.92). Results: Thirty experts from 10 countries completed the process (Argentina, Brazil, Chile, Colombia, Ecuador, Mexico, Panama, Peru, Uruguay, Venezuela). Panel consensus broadly converged with recommendations across current international HAE guidelines and consensus documents on core diagnostic work-up (C4 plus C1-INH antigen and function; 84% consensus), selective use of genetics (97% consensus), first-line targeted LTP (pdC1-INH, Lanadelumab, Berotralstat; 94% consensus), retention of on-demand therapy for breakthrough attacks and for patients without access to LTP, routine monitoring, and management in special populations. The principal novel finding was an implementation feasibility gap: frequent or constant interruptions in prophylaxis supply were reported by 19/30 experts (63%), including 13/23 (57%) practicing in settings where public or insurance coverage was reported. Across the panel, cost (19/30; 63%) and medicine availability (8/30; 27%) were the most commonly cited barriers, with additional constraints related to diagnostic testing access and administrative pathways. Conclusions: Latin American expert consensus largely converges with recommendations across current international HAE guidelines and consensus documents on diagnosis, acute management, prophylaxis selection, monitoring, and special-population care. The dominant divergence is not clinical disagreement but implementation feasibility—particularly access to diagnostic testing, financing mechanisms, medicine availability, and continuity of supply. These findings provide region-specific evidence to contextualize international recommendations and support implementation strategies tailored to Latin America.
- Open Access
- 30 March 2026
- Published by Colegio Mexicano de Inmunologia Clinica y Alergia, A. C. in Revista Alergia México
- Vol. 73 (1) , 93-104
Consenso de expertos mexicanos acerca de la profilaxis a largo plazo en pacientes con angioedema hereditario en México
ANTECEDENTES: El angioedema hereditario es una enfermedad genética rara y potencialmente mortal, caracterizada por episodios recurrentes de edema subcutáneo y submucosa mediado por bradicinina, con impacto sustancial en la morbilidad, la calidad de vida y el uso de recursos sanitarios. La incorporación de nuevas terapias dirigidas ha modificado el paradigma de la profilaxis de largo plazo; sin embargo, su implementación depende de condiciones clínicas y, de forma crítica, determinantes estructurales y de acceso, propios del sistema de salud. OBJETIVO: Caracterizar de manera integral el tratamiento profiláctico del angioedema hereditario en México, con énfasis en el diagnóstico, la profilaxis a largo plazo, el acceso y la disponibilidad terapéutica, la percepción del control de la enfermedad y la aplicabilidad de recomendaciones clínicas, a partir de la opinión estructurada de especialistas nacionales. MÉTODOS: Análisis descriptivo y analítico de los datos correspondientes a México obtenidos mediante un ejercicio Delphi estructurado, con especialistas con experiencia en el tratamiento de angioedema hereditario. Se evaluaron las prácticas de diagnóstico, el proceso de selección y prescripción de terapias profilácticas, tratamientos poco recomendados, problemas de disponibilidad y acceso, y percepción clínica del control de la enfermedad y la aplicabilidad de guías internacionales. RESULTADOS: Los especialistas reportaron una alta alineación conceptual con las recomendaciones clínicas vigentes. La profilaxis a largo plazo se centró predominantemente en lanadelumab, con uso limitado de concentrados de C1-INH y ausencia de berotralstat. Aunque el sistema de salud público otorga cobertura del tratamiento, persisten las barreras relacionadas con disponibilidad y costos, lo que condicionó el acceso efectivo y la continuidad terapéutica. Las guías clínicas fueron consideradas altamente aplicables; no obstante, se identificó una brecha entre el tratamiento recomendado y el factible en la práctica cotidiana. CONCLUSIONES: El tratamiento profiláctico de pacientes con angioedema hereditario en México refleja avances clínicos relevantes y un enfoque alineado con estándares contemporáneos; sin embargo, persisten limitaciones estructurales que restringen la implementación sostenida e individualizada de la profilaxis. Entre las áreas prioritarias se incluyen el fortalecimiento del diagnóstico oportuno, el aseguramiento del acceso continuo a terapias dirigidas y la estandarización del seguimiento clínico. PALABRAS CLAVE: Angioedema hereditario; Morbilidad; Calidad de vida; Atención médica; Opinión de expertos; Profilaxis a largo plazo; Inhibidor de C1; Lanadelumab; Berotralstat; México.
- 30 March 2026
- Published by Colegio Mexicano de Inmunologia Clinica y Alergia, A. C. in Revista Alergia México
- Vol. 73 (1) , 93-104
Open AccessConsenso de expertos mexicanos acerca de la profilaxis a largo plazo en pacientes con angioedema hereditario en México
ANTECEDENTES: El angioedema hereditario es una enfermedad genética rara y potencialmente mortal, caracterizada por episodios recurrentes de edema subcutáneo y submucosa mediado por bradicinina, con impacto sustancial en la morbilidad, la calidad de vida y el uso de recursos sanitarios. La incorporación de nuevas terapias dirigidas ha modificado el paradigma de la profilaxis de largo plazo; sin embargo, su implementación depende de condiciones clínicas y, de forma crítica, determinantes estructurales y de acceso, propios del sistema de salud. OBJETIVO: Caracterizar de manera integral el tratamiento profiláctico del angioedema hereditario en México, con énfasis en el diagnóstico, la profilaxis a largo plazo, el acceso y la disponibilidad terapéutica, la percepción del control de la enfermedad y la aplicabilidad de recomendaciones clínicas, a partir de la opinión estructurada de especialistas nacionales. MÉTODOS: Análisis descriptivo y analítico de los datos correspondientes a México obtenidos mediante un ejercicio Delphi estructurado, con especialistas con experiencia en el tratamiento de angioedema hereditario. Se evaluaron las prácticas de diagnóstico, el proceso de selección y prescripción de terapias profilácticas, tratamientos poco recomendados, problemas de disponibilidad y acceso, y percepción clínica del control de la enfermedad y la aplicabilidad de guías internacionales. RESULTADOS: Los especialistas reportaron una alta alineación conceptual con las recomendaciones clínicas vigentes. La profilaxis a largo plazo se centró predominantemente en lanadelumab, con uso limitado de concentrados de C1-INH y ausencia de berotralstat. Aunque el sistema de salud público otorga cobertura del tratamiento, persisten las barreras relacionadas con disponibilidad y costos, lo que condicionó el acceso efectivo y la continuidad terapéutica. Las guías clínicas fueron consideradas altamente aplicables; no obstante, se identificó una brecha entre el tratamiento recomendado y el factible en la práctica cotidiana. CONCLUSIONES: El tratamiento profiláctico de pacientes con angioedema hereditario en México refleja avances clínicos relevantes y un enfoque alineado con estándares contemporáneos; sin embargo, persisten limitaciones estructurales que restringen la implementación sostenida e individualizada de la profilaxis. Entre las áreas prioritarias se incluyen el fortalecimiento del diagnóstico oportuno, el aseguramiento del acceso continuo a terapias dirigidas y la estandarización del seguimiento clínico. PALABRAS CLAVE: Angioedema hereditario; Morbilidad; Calidad de vida; Atención médica; Opinión de expertos; Profilaxis a largo plazo; Inhibidor de C1; Lanadelumab; Berotralstat; México.
- Open Access
- 2 March 2026
- Published by Open Exploration Publishing in Exploration of asthma & allergy
- Vol. 4, 1009110
Peanut allergy among schoolchildren in Mexico: findings from a national survey
Peanut allergy (PA) is a significant public health problem in Western countries; however, while some previous work has been conducted in Mexico among specific subgroups, the national prevalence of PA in the Mexican population remains unknown. This ENRADAL-MEX study aimed to estimate the prevalence of PA among Mexican schoolchildren. A total of 4,269 children aged 6–12 years were included (mean age: 8.7 years; 51.7% male). The national prevalence of adverse food reactions was 9.5%; among these, 16 cases (0.37%) were associated with peanut consumption, but only 11 presented symptoms within the first hour after ingestion, yielding a PA prevalence of 0.26% (95% CI: 0.14–0.47%). Five cases corresponded to convincing non-severe reactions, and the other five to convincing severe reactions (prevalence of 0.12%; 95% CI: 0.06–0.28%, each). Oral symptoms occurred in 54.5% of cases, and 63.6% also had tree nut allergy, with no reactions to other legumes. Since this national study is the first of its kind and indicates that PA is not currently a public health problem among Mexican schoolchildren, further research is encouraged for more comprehensive results.
- 2 March 2026
- Published by Open Exploration Publishing in Exploration of asthma & allergy
- Vol. 4, 1009110
Open AccessPeanut allergy among schoolchildren in Mexico: findings from a national survey
Peanut allergy (PA) is a significant public health problem in Western countries; however, while some previous work has been conducted in Mexico among specific subgroups, the national prevalence of PA in the Mexican population remains unknown. This ENRADAL-MEX study aimed to estimate the prevalence of PA among Mexican schoolchildren. A total of 4,269 children aged 6–12 years were included (mean age: 8.7 years; 51.7% male). The national prevalence of adverse food reactions was 9.5%; among these, 16 cases (0.37%) were associated with peanut consumption, but only 11 presented symptoms within the first hour after ingestion, yielding a PA prevalence of 0.26% (95% CI: 0.14–0.47%). Five cases corresponded to convincing non-severe reactions, and the other five to convincing severe reactions (prevalence of 0.12%; 95% CI: 0.06–0.28%, each). Oral symptoms occurred in 54.5% of cases, and 63.6% also had tree nut allergy, with no reactions to other legumes. Since this national study is the first of its kind and indicates that PA is not currently a public health problem among Mexican schoolchildren, further research is encouraged for more comprehensive results.
- Open Access
- 31 March 2025
- Published by Colegio Mexicano de Inmunologia Clinica y Alergia, A. C. in Revista Alergia México
- Vol. 72 (1) , 35-51
Non-IgE-mediated gastrointestinal food allergy. Updated literature review by the CMICA Food Allergy Committee
Background: Non-IgE-mediated gastrointestinal food allergy includes adverse reactions to food mediated by the innate immune system and cellular immunity. It is characterized by subacute or chronic gastrointestinal symptoms after ingestion of a relevant food allergen, making diagnosis difficult. Objective: To carry out an updated bibliographic review of non-IgE-mediated gastrointestinal food allergy, that summarizes incidence, pathophysiology, clinical manifestations, diagnostic tools and treatment. Methods: A search was conducted in the databases Medline, EMBASE, Scielo, Google Scholar and the Advanced Medicine Informatics Network (RIMA) using the keywords: non-IgE-mediated food allergy, allergic proctocolitis; cow’s milk-induced anemia; food protein-induced enteropathy; food protein-induced enterocolitis syndrome; Celiac disease and Heiner syndrome. The search was limited to articles published in English and Spanish from January 2015 to May 2024. Results: While progress has been made in the recognition of these diseases, the prevalence and pathophysiology remain uncertain. Involvement of the innate immune system and cellular immunity in gastrointestinal inflammation has been found, but further studies are needed to clarify the immunopathogenesis and associated biomarkers. Conclusions: Non-IgE-mediated gastrointestinal food allergy account for an unknown proportion of food allergies. Since there are no biomarkers or non-invasive confirmatory tests, the diagnosis relies on clinical features and is confirmed when the symptoms improve with elimination of the offending food. Management includes avoidance of the causative food from the diet, supportive treatment in case of accidental exposure, and nutritional counseling. Keywords: Non-IgE-mediated food allergy; Food protein-induced enterocolitis syndrome; Celiac disease; Allergic proctocolitis; Cow’s milk-induced anemia; Food protein-induced enteropathy; Heiner syndrome.
- 31 March 2025
- Published by Colegio Mexicano de Inmunologia Clinica y Alergia, A. C. in Revista Alergia México
- Vol. 72 (1) , 35-51
Open AccessNon-IgE-mediated gastrointestinal food allergy. Updated literature review by the CMICA Food Allergy Committee
Background: Non-IgE-mediated gastrointestinal food allergy includes adverse reactions to food mediated by the innate immune system and cellular immunity. It is characterized by subacute or chronic gastrointestinal symptoms after ingestion of a relevant food allergen, making diagnosis difficult. Objective: To carry out an updated bibliographic review of non-IgE-mediated gastrointestinal food allergy, that summarizes incidence, pathophysiology, clinical manifestations, diagnostic tools and treatment. Methods: A search was conducted in the databases Medline, EMBASE, Scielo, Google Scholar and the Advanced Medicine Informatics Network (RIMA) using the keywords: non-IgE-mediated food allergy, allergic proctocolitis; cow’s milk-induced anemia; food protein-induced enteropathy; food protein-induced enterocolitis syndrome; Celiac disease and Heiner syndrome. The search was limited to articles published in English and Spanish from January 2015 to May 2024. Results: While progress has been made in the recognition of these diseases, the prevalence and pathophysiology remain uncertain. Involvement of the innate immune system and cellular immunity in gastrointestinal inflammation has been found, but further studies are needed to clarify the immunopathogenesis and associated biomarkers. Conclusions: Non-IgE-mediated gastrointestinal food allergy account for an unknown proportion of food allergies. Since there are no biomarkers or non-invasive confirmatory tests, the diagnosis relies on clinical features and is confirmed when the symptoms improve with elimination of the offending food. Management includes avoidance of the causative food from the diet, supportive treatment in case of accidental exposure, and nutritional counseling. Keywords: Non-IgE-mediated food allergy; Food protein-induced enterocolitis syndrome; Celiac disease; Allergic proctocolitis; Cow’s milk-induced anemia; Food protein-induced enteropathy; Heiner syndrome.
- Open Access
- 8 January 2022
- Published by Colegio Mexicano de Inmunologia Clinica y Alergia, A. C. in Revista Alergia México
- Vol. 69 (Supl1) , s81-s93
Alergia a penicilina
Los betalactámicos son los antimicrobianos más utilizados por su seguridad y eficacia. En este grupo se incluyen las penicilinas, las cefalosporinas, los carbapenémicos y los monobactámicos. La penicilina constituye la primera causa de alergia a medicamentos: 10 a 20 % de la población se etiqueta como alérgica a la misma, en muchas ocasiones erróneamente. Se ha reportado reacción cruzada entre penicilinas y cefalosporina en 2 a 5 %. No hay reacción cruzada entre penicilinas y aztreonam, pero sí con ceftazidima. En la fisiopatología de las reacciones de hipersensibilidad a penicilina se incluyen todos los mecanismos de la clasificación de Gell y Coombs. La estratificación de acuerdo con el riesgo permite tomar la decisión más objetiva para etiquetar al paciente como alérgico. En la evolución natural de la alergia a la penicilina, 80 a 90 % de los pacientes pierde dicha sensibilidad a los 10 años. De ser indispensable, el paciente puede ser sometido a un protocolo de desensibilización. El médico inmunoalergologo es una pieza clave en la selección del paciente, la elaboración de los protocolos de reto y la desensibilización en un ambiente controlado.
- 8 January 2022
- Published by Colegio Mexicano de Inmunologia Clinica y Alergia, A. C. in Revista Alergia México
- Vol. 69 (Supl1) , s81-s93
Open AccessAlergia a penicilina
Los betalactámicos son los antimicrobianos más utilizados por su seguridad y eficacia. En este grupo se incluyen las penicilinas, las cefalosporinas, los carbapenémicos y los monobactámicos. La penicilina constituye la primera causa de alergia a medicamentos: 10 a 20 % de la población se etiqueta como alérgica a la misma, en muchas ocasiones erróneamente. Se ha reportado reacción cruzada entre penicilinas y cefalosporina en 2 a 5 %. No hay reacción cruzada entre penicilinas y aztreonam, pero sí con ceftazidima. En la fisiopatología de las reacciones de hipersensibilidad a penicilina se incluyen todos los mecanismos de la clasificación de Gell y Coombs. La estratificación de acuerdo con el riesgo permite tomar la decisión más objetiva para etiquetar al paciente como alérgico. En la evolución natural de la alergia a la penicilina, 80 a 90 % de los pacientes pierde dicha sensibilidad a los 10 años. De ser indispensable, el paciente puede ser sometido a un protocolo de desensibilización. El médico inmunoalergologo es una pieza clave en la selección del paciente, la elaboración de los protocolos de reto y la desensibilización en un ambiente controlado.